Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
saRNA Marburg vaccine
- Development stage
- Unknown
- Lead developer
- Imperial College London
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The saRNA Marburg vaccine is a self-amplifying RNA (saRNA) vaccine candidate developed by Imperial College London for the prevention of Marburg virus disease. It utilizes a self-amplifying RNA platform, typically derived from an alphavirus backbone (such as Venezuelan equine encephalitis virus), which allows for the intracellular replication of the RNA template. This mechanism potentially leads to higher protein expression and stronger immune responses at lower doses compared to conventional mRNA vaccines. The vaccine encodes the Marburg virus glycoprotein (GP) and is formulated in lipid nanoparticles (LNPs) for intramuscular administration. It is currently being evaluated in a Phase I clinical trial (NCT05391360) alongside similar saRNA vaccines for Ebola and Lassa fever.
- Other names
- self-amplifying RNA Marburg vaccine
02
Targets
PYG (Glycogen phosphorylase)
Beyond the preview
Go deeper on saRNA Marburg vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on saRNA Marburg vaccine.